Cleocin

By C. Vasco. University of California, Irvine.

Studies that evaluated one rate-control procedure versus another did not find differences in rate control or all- cause mortality but did demonstrate an improvement in exercise capacity among those in a biventricular pacing group compared with right ventricular pacing discount cleocin 150 mg overnight delivery. Our findings underscore the need for additional studies to compare rate-control procedures with rate-control drugs or other procedural interventions with in relation to these outcomes cheap cleocin 150 mg visa. Although based on direct and mostly consistent evidence buy generic cleocin 150mg line, the low number of studies order cleocin discount, imprecise findings, and inability to determine a summary effect given the variability in study design and population lowered our confidence in the evidence. Strength of evidence domains for rate-control procedures versus drugs Domains Pertaining to SOE SOE and Number of Magnitude of Outcome Studies Risk of Consistency Directness Precision Effect (Subjects) Bias (95% CI) Ventricular 3 (175) RCT/Low Consistent Direct Imprecise SOE=Moderate Rate Control Using different metrics, all 3 studies found that patients in the procedure arm had a significantly lower heart rate at 12 months than those on drugs All-Cause 2 (201) RCT/Low Consistent Direct Imprecise SOE=Low Mortality No significant difference CV Mortality 1 (102) RCT/Low NA Direct Imprecise SOE=Low No significant difference Exercise 2 (135) RCT/Low Consistent Direct Imprecise SOE=Low Capacity Studies did not show significant differences between procedure and drug arms Quality of Life 2 (135) RCT/Low Inconsistent Direct Imprecise SOE=Insufficient Abbreviations: CI=confidence interval; NA=not applicable; RCT=randomized controlled trial; SOE=strength of evidence 39 Table 9. Strength of evidence domains for one rate-control procedure versus another Domains Pertaining to SOE SOE and Number of Magnitude of Outcome Studies Risk of Consistency Directness Precision Effect (Subjects) Bias (95% CI) Ventricular 1 (40) RCT/Low NA Direct Imprecise SOE=Low Rate Control No difference between those assigned to anterior vs. Antiarrhythmic Drugs and Electrical Cardioversion for Conversion to Sinus Rhythm KQ 4: What are the comparative safety and effectiveness of available antiarrhythmic agents and electrical cardioversion for conversion of atrial fibrillation to sinus rhythm? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest? Key Points • Based on 4 RCTs (2 good, 2 fair quality) involving 411 patients, use of a single biphasic waveform is more effective in restoring sinus rhythm than use of a single monophasic waveform in patients with persistent AF (high strength of evidence). Description of Included Studies A total of 42 RCTs involving 5,780 patients were identified that assessed the use of antiarrhythmic drugs or electrical cardioversion for the conversion of AF to sinus rhythm 140,170-181 (Appendix Table F-4). Thirteen studies were considered to be of good quality, 27 of fair 144,145,147,149,182-204 205,206 quality, and 2 of poor quality. The studies were published from the years 170,171,188,196 2000 through 2011; however, all but four studies were published in 2007 or earlier. Only 7 studies included sites in the United States; 25 140,144,145,147,170,175-179,187,188,191-196,200-206 included sites in Europe. The study population consisted 144,145,147,170-172,175-178,183,185-187,192-195,197-199,202- entirely of patients with persistent AF in 25 studies, 204,206 189 entirely of patients with paroxysmal AF in 1 study, and entirely of patients for whom 174,195 prior rate- or rhythm-control therapy had been ineffective in 2 studies. Funding was unclear 140,144,147,170,172,173,175,179,181,183,185-188,190-206 or not reported in 31 studies. Seven studies used 145,171,174,176,178,180,184 industry funding, none was government-only funded, and eight were funded 145,149,171,174,177,178,182,189 by nongovernment/nonindustry sources. In the majority of studies, the 145,179,181,183-187,193,195,197-203,206 setting was not reported (18 studies ). Of the remaining studies, 7 140,144,174,177,182,191,205 149,170,173,189,190 were inpatient, 5 were in the emergency room, 10 were 147,171,172,175,176,178,180,192,194,204 188,196 outpatient, and 2 were in more than one setting. Figure 5 represents the treatment comparisons evaluated for this KQ. Overview of treatment comparisons evaluated for KQ 4 aLines running from one oval back to the same oval (e. Abbreviations: KQ=Key Question; J=Joules; Tx=treatment Twenty-one studies compared methods of external electrical cardioversion, four studies 178 199,205 compared electrical cardioversion augmented by medications (metoprolol, verapamil, 195 and ibutilide ) with electrical cardioversion alone, and eight studies evaluated the efficacy of drugs used both prior to and after external electrical cardioversion (amiodarone [five 144,149,180,181,204 144,204 145,147,149,204,206 studies ], diltiazem [two studies ], digoxin [five studies ], 145,147,206 149,180,181 verapamil [three studies, ], sotalol [three studies ]). Nine studies compared drugs 140,170,177,188-193 without (or prior to) external electrical cardioversion. No study compared electrical cardioversion directly with pharmacological cardioversion. Of the 42 studies, 3 had a 170,180,193 181,192 placebo arm, and 2 had a “control” arm that was not included in this review. The remaining 36 studies had 2 intervention arms each. The primary outcome reported for this KQ was restoration of sinus of rhythm within a specified time period following the intervention. This time period ranged from immediately following the intervention to 6 weeks following the intervention. Several studies presented outcome data at multiple time points following the intervention, while others assessed time to outcome within a prespecified time frame. Only three studies did not report restoration of sinus 194,199,205 rhythm. Of these, one assessed maintenance of sinus rhythm at 1 week following 199 electrical cardioversion or verapamil plus electrical cardioversion, another reported 42 194 maintenance of sinus rhythm 1 month after electrical cardioversion, and the third reported recurrence of AF within 1 week following verapamil with electrical cardioversion versus 205 electrical cardioversion alone. Three studies reported an outcome relevant to this KQ in addition to restoration of sinus rhythm. One study reported all-cause mortality, mixed embolic events, and maintenance of sinus 185 191 rhythm at 6 weeks; one reported recurrence of AF within 24 hours after cardioversion; and 202 one reported recurrence of AF within 1 minute of electrical cardioversion. Detailed Synthesis Comparisons of Various Methods for External Electrical Cardioversion Overview Twenty-one studies (2,996 patients) compared different methods of external electrical cardioversion. Nine studies (1,219 patients) compared a biphasic waveform with a monophasic waveform (Table 10), and 4 studies (393 patients) compared anterolateral versus anteroposterior positioning of the defibrillation electrodes (paddles in 2 studies, paddles and/or gel pads in 1 175,183,187,202 study, and pads in 1 study). Three studies (432 patients) included a comparison of an 172,185,186 initial 200 J shock with an initial 360 J shock. The remaining five studies addressed 197 182 comparisons in polarity (one study ), shapes of the biphasic waveform (one study ), 176 composition of the cardioversion electrodes (one study ), and different amounts of energy 171,198 delivered (two studies ). Among the 9 studies comparing a biphasic waveform with a monophasic waveform, 8 assessed restoration of sinus rhythm at 0 or 30 minutes after cardioversion, and 1 assessed 194 maintenance of sinus rhythm at 1 month following electrical cardioversion. Only two studies 194,203 included only patients with persistent AF, and one study included only patients for whom a 174 prior rate- or rhythm-control therapy was ineffecitve. One study also included an assessment 203 of recurrence of AF within 1 minute following initial cardioversion. Three studies were of good quality, and six were of fair quality. Among these nine studies, mean/median population age ranged from 55–70 years; data on AF type and heart failure prevalence were generally not reported. Studies evaluating biphasic versus monophasic waveform Study Biphasic Protocol Monophasic N Outcomes Assessed Protocol 184 Ambler, 2006 100 J, 200 J, 300 70 J, 110 J, 150 J, 128 − Restoration of SR J, 360 J, 360 J 200 J, 360 J immediately − Restoration of SR at 30 minutes Kawabata, 50 J, 100 J, 150 J, 100 J, 200 J, 300 154 − Restoration of SR after 173 2007 175 J J, 360 J cumulative shocks (IV amiodarone) (IV amiodarone) − Restoration of SR after 1st shock 174 Khaykin, 2003 150 J, 200 J, 360 J Single 360 J 56 − Restoration of SR 194 Marinsek, 2003 70 J, 100 J, 150 J, 100 J, 200 J, 300 83 − Maintenance of SR at 1 200 J J, 360 J month Mortensen, 75 J, 100 J, 150 J, 100 J, 150 J, 200 95 − Restoration of SR 196 2008 200 J J, 300 J, 360 J immediately after cumulative shocks − Restoration of SR after 1st shock 179 Page, 2002 100 J, 150 J, 200 100 J, 150 J, 200 203 − Restoration of SR after 4 J, 200 J biphasic J, 200 J biphasic shocks or 360 J or 360 J − Restoration of SR after 3 monophasic monophasic shocks − Restoration of SR after 2 shocks − Restoration of SR after 1 shock 200 Ricard, 2001 150 J, 150 J 150 J, 360 J 57 − Restoration of SR after all shocks − Restoration of SR after 1 shock 201 Scholten, 2003 120–200 J 200–360 J 277 − Restoration of SR after 1st sequence sequence shock − Restoration of SR after 2nd shock Siaplaouras, 120 J, 150 J, 200 200 J, 300 J, 360 216 − Restoration of SR 203 2004 J, 200 J J, 360 J − Recurrence of AF within 1 minute Abbreviations: AF=atrial fibrillation; J=Joules; N=number of patients; SR=sinus rhythm Four studies (393 patients) compared anterolateral vs. One study was of 175 183,187,202 good quality, and three were of fair quality. One study was conducted in the outpatient 175 setting; the other three did not specify the setting. All four studies included only patients with persistent AF. The mean age of patients receiving the anterolateral approach ranged from 58–68 years, and the mean age of patients receiving the anteroposterior approach ranged from 62–67 years. All four studies assessed restoration of sinus rhythm immediately after the external electrical cardioversion, all four were conducted in Europe, and all four were single-center studies. LVEF was reported only in three studies, and the mean ranged from 49–60 percent in those receiving the anterolateral approach and 49–59 percent in those receiving the anteroposterior approach. Six studies assessed different external electrical cardioversion protocols for conversion of AF. In three of these (432 patients) there was a comparison between an initial monophasic 172,185,186 185,186 energy of 200 J and 360 J. Two of these were single-center studies, and one was 44 172 185,186 172 multicenter; two were conducted in Europe, and one in the United States. All three studies were composed entirely of patients with persistent AF, and all utilized monophasic waveforms with varying electrode positioning; in two, patients who did not convert with the first 172,186 shock received a subsequent shock. All three studies comparing monophasic shocks of 200 J and 360 J assessed restoration of sinus rhythm immediately after the electrical cardioversion procedure. In the other three studies assessing cardioversion protocols, different biphasic 171,182,198 energies were evaluated. In one of these, the different energy protocols also involved 182 different biphasic wave shapes (truncated vs. Two of the studies were composed 171,198 182 entirely of patients with persistent AF; the type of AF was not reported in the third study. This was a multicenter study in the United States and included only patients with persistent AF. The study was of fair quality; however, errors in the publication prevented collection of accurate baseline characteristics. Both biphasic and monophasic waveforms were tested, and the outcome was restoration of sinus rhythm within 30 seconds; however, statistical testing was not performed on this outcome measure. Finally, a single study compared steel paddles to adhesive pads for electrical 176 cardioversion.

Here the vital community health in the Democratic Republic contribution made by health researchers as of the Congo (6) order 150 mg cleocin free shipping. Te most expedient indicators part of the health workforce is underscored changed as programmes matured buy 150 mg cleocin mastercard. Geographical distribution of research capacity in Africa Research output (Number of articles per city) 31–99 100–249 250–499 500–999 >1000 R&D buy generic cleocin 150mg, research and development order cleocin without a prescription. Note: Mapping of top 40 African cities by research output shows hotspots and coldspots of R&D activity and highlights inequi- ties in R&D productivity across the continent. Alongside the numerous exam- courses ofered by the International Union ples of “north–south” research collaboration run against Tuberculosis and Lung Disease and a variety of training schemes for young research- Médecins Sans Frontières (MSF) Luxembourg ers – such as those ofered by TDR (www. Even where there are shortages of money int/tdr), the Training Programs in Epidemiology to do the research in Africa, there is an appe- and Public Health Interventions Network tite for career development through mentorship 104 Chapter 4 Building research systems for universal health coverage Box 4. Principles of research partnership Further details of these 11 principles can be found in Guidelines for research in partnership with developing countries prepared by the Swiss Commission for Research Partnership with Developing Countries (64). The 11 principles (with minor adaptation) are as follows: 1. Decide on research objectives together, including those who will use the results. Build mutual trust, stimulating honest and open research collaboration. Share information and develop networks for coordination. Create transparency in financial and other transactions. Monitor and evaluate collaboration, judging performance through regular internal and 1. Disseminate the results through joint publications and other means, with adequate communication to those who will finally use them. Apply the results as far as is possible, recognizing the obligation to ensure that results are used to benefit the target group. Share the benefits of research profits equitably including any profit, publications and patents. Increase research capacity at individual and institutional levels. Build on the achievements of research – especially new knowledge, sustainable development and research capacity. For instance, African research- contrast, research spending by two national ers have argued that support for research on health departments (England and Scotland) is neglected tropical diseases should not be the oriented to treatment evaluation, disease man- sole responsibility of external donors. Tese are believe that their own governments must also diferent but complementary and point to fund- take responsibility for providing infrastructure ing gaps that need to be flled, perhaps from and job opportunities (65, 68). Tis is an argument not Just as research needs money, the development of only for research monitoring but also for greater research capacity needs a mechanism for track- harmonization between funding bodies. Te virtues of having a standard method Te eight areas of research outlined in Box 2. Contrasting but complementary classifcation – a disease code is combined with profles of health research a description of the research purpose – indicat- spending, United Kingdom ing that there is a common understanding of C004–F004. Te Ireland, 2009–2010 next step in reconciling diferent schemes could A. Medical research organizations take one of two directions: either agreement to 50 adopt the same system, or reliance on computer sofware to translate and map the current variety 40 of classifcation systems to a common standard 30 (71). Te best approach will be the one that most easily achieves the main goal, which is to assure 20 transparency and accountability in research funding (70). Despite the impor- Type of research study tance of good accounting in research, the evaluation Wellcome Trust Medical Research Council of both need and cost are underdeveloped skills. Funding for TB operational research illus- trates the challenge of assessing need. National health departments able expenditure (budget) for TB operational 50 research has been set at US$ 80 million annually, calculated as 1% of the expenditure of national 40 TB control programmes (72). Against this arbi- 30 trary spending target, which is far lower than that for any other area of TB research, the avail- 20 able funds totalled 76% of assessed need. Tis is a higher percentage than for any other area of 10 research (Fig. Te danger here is to con- 0 clude that the need for operational research has 1 largely been satisfed. While the Global Plan to Type of research study Stop TB has successfully highlighted the need to England Scotland invest in R&D for technology, a more objective method is needed for calculating the TB opera- Types of research: 1, underpinning; 2, etiology; 3, preven- tional research budget, especially in light of the tion; 4, detection and diagnosis; 5, treatment development; widely-held view that too little efort is devoted 6, treatment evaluation; 7, disease management; 8, health systems and services (Box 2. Note: For each of the four organizations, percentages sum to On the question of costing, the calculation of 100%. Adapted, by permission of the publisher, from the UK Clinical It refers to the indirect costs that are harder to Research Collaboration (69). Research institutions 106 Chapter 4 Building research systems for universal health coverage Building research institutions Fig. Global expenditures and budget gap in tuberculosis R&D by and networks research category, 2010 Te Global Health Trials network has expressed a view of capacity-building that is shared by other health research networks (Box 4. In the con- text of research networks, “capacity” is seen as the establishment of a community of researchers based in lower-income countries who can devise and validate methods and operational tools for improving health, and who share local and global solutions to make pragmatic and locally- led development possible (79). Putting the spotlight on collaboration between lower-income countries does not mean neglecting the traditional links through R&D, research and development. Reproduced, by permission of the publisher, from Treatment research studies of each group differs from that Action Group (73). For instance, clinical trials in poorer countries have focused largely on communicable rather in low- and middle-income countries have the than noncommunicable diseases. In contrast, task of persuading external donors to contribute researchers in richer countries have enormous to indirect costs, and also to align their research expertise in studying noncommunicable dis- priorities in contributing to direct costs. Their expertise will be in demand as the these problems were confronted – and solved – by need for research on these diseases continues to the International Centre for Diarrhoeal Diseases rise worldwide (79). Solutions were found, in part by adopting a transparent approach to fnancial monitoring Defning and implementing and evaluation. ICDDR,B explicitly defned and norms and standards measured activities, outputs and outcomes in the areas of research, clinical services, teaching, and Codes of practice for the responsible conduct management and operations. Developing research networks Initiative to Strengthen Health Research Capacity in Africa (ISHReCA) ISHReCA (ishreca. ISHReCA aims to expand research capacity in four ways: (i) it provides a platform for African health researchers to discuss ways of building sustainable capacity for health research in Africa; (ii) it promotes an African-led agenda for health research, negotiating with funders and partners concerning support for, and harmonization of, research initiatives; (iii) it advocates for increased commitment to research by national governments and civil society, emphasizing the translation of research into policy and practice; and (iv) it seeks novel ways to garner regional and international support for health research in Africa. African Network for Drugs and Diagnostics Innovation (ANDI) Launched in 2008, ANDI (www. To realize this vision, ANDI is building capacity that supports pharmaceutical research, development and manufacturing to improve access to medicines. Specific activities include the development of a portfolio of high-quality, pan-African pharmaceutical R&D innovation projects, project coordination and management, including intellectual property management. Vital to ANDI are more than 30 African institutions which are recognized as research centres of excel- lence and are committed to sharing expertise, knowledge, research equipment and facilities (61, 78). Global Health Trials Global Health Trials (globalhealthtrials. An e-learning centre offers short courses, seminars and a library. Pan-African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA) North–south research collaboration, such as that fostered by the European and Developing Countries Clinical Trials Partnership (www. The EDCTP 14-country partnership works to “accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria, with a focus on phase II and III clinical trials in sub-Saharan Africa”. An offshoot of EDCTP, PanACEA is a network of 11 linked clinical trial sites in six African countries, supported by European research organizations and pharmaceutical companies. The initial aim of the network was to investigate the role of moxifloxacin in reducing treatment durations for TB. However, PanACEA has a wider ambition – to establish collaboration rather than competition as a driving force in the conduct of high-quality clinical and regulatory trials. Research for Health Africa (R4HA) The goal of R4HA (www.

To defend against this complication buy cleocin once a day, putative neuroprotective drugs and restorative therapies are levodopa is now routinely administered in combination currently being tested order 150mg cleocin otc. This chapter reviews the major thera- with a peripherally acting inhibitor of AADC generic cleocin 150 mg mastercard. In the United pies for PD and describes present advances and future direc- States discount 150 mg cleocin mastercard, levodopa is combined with the AADC inhibitor car- tions in the therapeutics of PD. The combination DISEASE of levodopa with an AADC inhibitor permits the use of lower doses of levodopa (by doubling its bioavailability) Levodopa and reduces the incidence of peripheral dopaminergic side Since its introduction in the late 1960s (8), levodopa (L- effects such as nausea, vomiting, and hypotension. In most 3,4-dihydroxyphenylalanine) has remained the single most patients, a daily dose of 75 mg of carbidopa is sufficient to effective antiparkinsonian agent, providing benefit to vir- inhibit AADC and prevent these side effects. Levodopa use is associated with even in the presence of an AADC inhibitor, 90% of levo- improved mobility, reduced disability, and prolonged sur- dopa is still metabolized by COMT (17). The involvement of dopaminergic systems the recent introduction of COMT inhibitors (see section in PD was first suspected in the late 1950s, following the below). In the same period, an animal and released in a spike-dependent manner in association study showed that movement slowness in rats, due to the with depolarization of the presynaptic neuron. The released catecholamine depletor reserpine, could be reversed with dopamine acts on postsynaptic dopamine receptors (possi- levodopa (13). The discovery that dopamine is depleted in bly in a volumetric manner). Its action is terminated primar- the striatum of PD patients soon followed (14). This in ily by a very rapid presynaptic reuptake system that is antag- turn gave rise to the notion that a dopamine replacement onized by cocaine. It can be degraded either intracellularly strategy might be useful in PD, and the therapeutic role of or extracellularly by monoamine oxidase (MAO) and levodopa in patients with PD was subsequently established COMT enzymes to yield homovanillic acid (HVA)(9). Levodopa is itself largely inert, and its thera- MAO has two subtypes; A, which is primarily intracellular, peutic and adverse effects result from the decarboxylation and B, which is primarily extracellular (18). After oral administration, levodopa absorption occurs family) and five receptor subtypes (D1–D5) have been mo- in the small bowel by way of the active transport system lecularly cloned to date (19). The D1 receptor family is for large neutral amino acids. Thus, it is possible that other characterized by positive coupling with adenylate cyclase large neutral amino acids such as lysine and phenylalanine formation, whereas D2 receptors have an affinity for neuro- that are present in protein-rich foods can compete with and leptic agents and activation inhibits adenylate cyclase (20). Indeed, it is becoming increasingly clear ences symptomatic orthostatic hypotension, the possibility that activation of different receptors, the same receptor with that he or she suffers from MSA with autonomic involve- different agents, and the same receptor with the same agent ment should be considered. In the early stages of PD, the duration diffusely distributed throughout the CNS: motor striatum of benefit following a single dose of levodopa is long lasting (D1, D2), hippocampus (D5), frontal cortex and amygdala and far exceeds the plasma half-life of the drug (60 to 90 (D4), hypothalamus (D3, D5), and mesolimbic system minutes) (32). The precise role of each of these receptors in motor served capacity of presynaptic dopaminergic terminals of function remains unknown; however, it is likely that this nigrostriatal neurons to store dopamine and regulate its re- wide distribution accounts for the diverse pattern of func- lease. However, after a few years of levodopa therapy, there tional effects that can be obtained when exogenous levodopa is further neuronal degeneration, and the duration of benefit is administered to PD patients. Although most attention following each dose of levodopa is shortened in duration. Further, the periods of good ganglia regions including the substantia nigra pars reticularis motor function that characterize 'on' periods now becomes (SNr), the subthalamic nucleus (STN), the globus pallidus complicated by involuntary movements known as dyskine- pars interna (GPi), and the globus pallidus pars externa sia. These are usually choreiform in nature and occur in (GPe) (21). Activation of dopaminergic receptors in these association with the peak plasma concentration of the drug. Indeed, although levodopa dramatically improves the In this situation they are referred to as diphasic dyskinesia motor signs and symptoms of PD, it also has effects on (34). Manipulating the dose and frequency of levodopa ad- vision, memory, mood, reward-related learning, and addic- ministration is the usual therapeutic approach to the onset tion (22–30). Eventually, it may become virtually impossi- benefits can be dramatic, and improvement can be obtained ble to achieve a dose of levodopa that provides motor in all of the cardinal signs and symptoms of PD. Levodopa benefits without inducing dyskinesia, and patients may has also been shown to provide a dose-dependent beneficial cycle between intolerable dyskinesia and intolerable parkin- effect on mood and anxiety in PD patients that increases sonism. These important nonmo- In the early stages of motor fluctuation, increasing the tor effects can contribute to the benefits associated with half-life of levodopa by coadministration of a COMT inhib- the levodopa response. Indeed, more than 30 years after its itor may be helpful (see COMT Inhibitors, below). Sus- introduction, no other medication provides antiparkinso- tained-release formulations of levodopa (Sinemet CR, Ma- nian benefits that are superior to levodopa (30,31). These are makes them difficult to employ in routine practice, espe- usually seen during the titration phase and can be mini- cially for patients with complex motor complications. Low- mized by initiating levodopa at a low dose and titrating protein diets or redistribution diets with restriction of the slowly to the desired clinical effect. Persistent nausea and protein intake until the later part of the day may provide vomiting can specifically be handled by adding supplemen- some short-term benefits by facilitating levodopa absorption tal doses of carbidopa (Lodosyn), or using the peripheral and thereby improving motor performance (36). Dyskine- dopamine receptor antagonist domperidone (available in sias are difficult to treat medically, other than by lowering Canada and Europe) in doses of 10 mg 30 minutes before the dose of dopaminergic agent, and this in turn can be the levodopa dose. Postural hypotension can be managed associated with worsening parkinsonism as described above. When motor complications are fully persists, pharmacologic agents such as fluorocortisone and developed, medical therapies are for the most part ineffec- 1798 Neuropsychopharmacology: The Fifth Generation of Progress tive and patients may be considered for surgical intervention the degree of neuronal synchrony, and neuronal firing fre- (see below). Thus, despite the best of existing medical ther- quency (46). Chase and his colleagues initially postulated that lev- output neurons in the basal ganglia so as to disrupt their odopa-related motor fluctuations develop because of the abnormal neuronal firing pattern and the communication of progressive loss of nigrostriatal neurons and a loss of their misinformation from basal ganglia to motor cortical regions. A a dose of levodopa in patients with advancing disease, de- second approach has been directed at modulating dysregu- spite the fact that levodopa peripheral pharmacokinetics lated signaling pathways in striatal neurons leading to ab- remain stable in all stages of PD (39,40). This 'storage normal phosphorylation of N-methyl-D-aspartate (NMDA) hypothesis' presumed that with the loss of dopamine termi- receptors (49). This concept has led to studies of NMDA nals, central buffering capacity is lost, and striatal dopamine receptor antagonists and other agents that interfere with levels become dependent on the peripheral availability of intracellular signals as a means of treating levodopa-induced levodopa. Finally, and per- fluctuate in parallel with the fluctuating plasma levodopa haps most importantly from the standpoint of the clinician, levels that accompany intermittent administration of oral are the use of long-acting dopaminergic agents based on levodopa therapy. With increasing disease severity, there is attempts to provide more physiologic continuous dopami- progressive degeneration of dopamine terminals with fur- nergic stimulation to striatal dopamine receptors and avoid ther loss of their buffering capacity and consequent exposure pulsatile stimulation of striatal dopamine receptors (51). How- demonstrated that PD patients randomized to initiate ther- ever, the storage hypothesis cannot account for the fact that apy with a dopamine agonist have significantly reduced risk apomorphine has similar pharmacokinetic and pharmaco- of developing motor complications compared to those ran- dynamic responses with advancing disease severity as does domized to start with levodopa (30,31). This implies that postsynaptic tion, and neuropsychiatric problems such as hallucinations mechanisms must play some role in the pathophysiology of and confusion. These are most likely to occur in the elderly levodopa-related motor complications. The Current evidence indicates that levodopa-induced motor initial hallucinatory episodes usually consist of benign visual complications are related to a sequence of events that in- hallucinations that are often a greater source of concern to clude abnormal pulsatile stimulation of the dopamine recep- the family than the patient, who retains insight into the tor by dopaminergic agents with a short plasma half-life, nature of the problem. However, patients who experience dysregulation of downstream genes and proteins, and al- levodopa-induced hallucinations are more likely to go on tered neuronal firing patterns (see ref. An Alzheimer-type dementia view of this topic; also see below). In support of this concept, can occur in as many as one-third of PD patients, particu- it has been shown that motor complications in parkinsonian larly if they have onset after the age of 70 years. Managing monkeys are induced by short-acting dopaminergic agents hallucinations and confusion in a levodopa-treated patient such as levodopa, which induce pulsatile simulation of re- (1) involves (a) ruling out other temporary causes of mental ceptors, but not by long-acting dopamine agonists, which dysfunction, such as infection, electrolyte imbalance, other more closely simulate the normal tonic activation of dopa- brain lesions; (b) elimination of nonparkinsonian medica- mine receptors (43). Indeed, intermittent administration of tions that are not essential and can impair cognition, (c) a short-acting dopamine agonist induces dyskinesia, whereas elimination of antiparkinsonian drugs that are prone to continuous administration of the same short-acting agonist causing delirium such as anticholinergics, amantadine, sele- does not (44). Further, altered expression of genes such as giline, and dopamine agonists; thereafter the levodopa dose preproenkephalin (PPE) in striatal neurons have been should be reduced to the lowest dose that provides satisfac- recorded in association with the development of dyskinesia tory control of mobility; and (d) finally, low-dose therapy in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- with atypical neuroleptics can be considered. Finally, levodopa-induced alterations an atypical neuroleptic that has minimal parkinsonian ef- in neuronal firing patterns have been described in dyskinetic fects and has been found to be useful in the treatment of monkeys, which include changes in firing bursts and pauses, psychotic symptoms in PD patients (53). Accordingly, treatment is initiated with a dose of formulations of levodopa can be made by adding water and 12. Hallucinations can usually be con- and offer little additional advantage for most PD patients. Clozapine is associ- Rapidly absorbed methyl and ethyl ester formulations of ated with a small risk of hematologic side effects and peri- levodopa are currently being assessed experimentally. Respiradone (Respiradol), In summary, levodopa continues to be an important olanzapine (Xyprexa), and quietapine (Seroquel) are alterna- component of the therapeutic armamentarium for PD, but tive atypical neuroleptics, but they have been less thoroughly it is associated with troublesome complications and some studied than clozapine for PD psychosis, and anecdotal re- parkinsonian features do not respond.

In contrast buy discount cleocin, hyperuricem ia usually is the result of drug interference with purine metabolism (didanosine) or tubular urate secretion (pyrazinam ide and etham butol) best buy for cleocin. In the absence of clinical m anifestations that readily explain acid-base FIGURE 7-18 or electrolyte disturbances buy cleocin 150mg with amex, a careful review of the pharm acopeia Drugs causing electrolyte com plications cheap cleocin 150 mg with mastercard. A num ber of drugs used used to treat patients with H IV infection is m andated. Extensive in the treatm ent of patients with AIDS can induce acid-base or reviews of the com plications associated with drugs are available electrolyte abnorm alities from direct renal toxicity (didanosine, [127,128]. The clinical presentation, laboratory findings, and course of acute tubular necrosis do not differ in patients with AIDS and those in other clinical settings. Prerenal azotemia, acute tubular necrosis Prevention includes correction of fluid and electrolyte abnormalities and dosage adjustments of Allergic interstitial nephritis potentially nephrotic drugs. Identification and withdrawal of the offending agents usually result Obstructive nephropathy in recovery of renal function. Dialysis m ay be needed before renal function im proves. Less Rhabdomyolysis, myoglobinuric acute renal failure frequent causes of acute renal failure include allergic acute interstitial nephritis; complicating Thrombotic thrombocytopenic purpura, hemolytic treatm ents with trim ethoprim and sulfam ethoxazole, rifam pin, or acyclovir; and acute uremic syndrome obstructive nephropathy, resulting from the intrarenal precipitation of crystals of sulfadiazine, Rapidly progressive glomerulonephritis acyclovir, urate, or protease inhibitors [134,139–146]. O bstructive uropathy without hydronephrosis also may develop in patients with lymphoma as a result of lymphomatous ureteropelvic infiltration or retroperitoneal fibrosis [147–149]. Rhabdomyolysis with myoglo- binuric acute renal failure usually occurs in the setting of cocaine use [150]. Instances of acute FIGURE 7-19 renal failure associated with intravascular coagulation related to thrombotic thrombocytopenic Causes of acute renal failure. Acute renal purpura (TTP) or hemolytic uremic syndrome (HUS) have been reported (vide infra). Rare failure is related to complications of AIDS, its causes of acute renal failure include disseminated microsporidian infection or histoplasmosis treatment, or the use of diagnostic agents in [151,152]. A clinical presentation of acute renal failure also can be seen in patients with acute about 20% of patients [129,130]. Acute tubu- immunocomplex postinfectious glomerulonephritis, crescentic glomerulonephritis, or fulminant lar necrosis occurs with a prevalence of 8% to HIV-associated glomerulosclerosis. An example of nonoliguric acute tubular 7 7 necrosis associated with administration of large doses of intravenous 6 6 acyclovir is illustrated, which was readily reversible on decreasing 5 5 the dose of acyclovir from 2. Patients infected with 4 4 HIV can exhibit a broad spectrum of conditions that may affect the 3 3 kidneys. Renal biopsy is useful for diagnostic and prognostic purpos- 2 2 es when the cause of acute renal failure is not clinically evident. In a 1 1 recent study of 60 patients with acute renal failure, a percutaneous 0 0 renal biopsy yielded a pathologic diagnosis in 13% that was not 1 2 3 4 5 6 7 8 expected clinically [154]. Day Renal Disease in Patients Infected with Hepatitis and Human Immunodeficiency Virus 7. Rao and Friedm an [155] com pared the course of 146 ACUTE RENAL FAILURE patients with severe acute renal failure (serum creatinine >6 m g/dL) infected with H IV with a group of 306 contem poraneous persons not infected with H IV but with equally severe acute renal failure. The patients infected with H IV were younger than those in the HIV Non-HIV group not infected (m ean age 38. O ver 80% of patients in each group Conservative 20 (14%) 42 (14%) recovered renal function when conservative therapy alone was sufficient. W hen dialysis Recovered 85% 83% NS intervention was needed, it was not initiated m ore often in the group with H IV than in the Needing dialysis 126 264 control group (42% and 24% , respectively; P<0. In those patients in whom dialysis Not initiated 42% 22% 0. O verall, the m ortality in Initiated 73 207 patients with severe acute renal failure was not significantly different in those with H IV Recovered 56% 47% NS infection from those in the group not infected with H IV (im m ediate m ortality, 60% and 56% , respectively; m ortality at 3 m onths, 71% and 60% , respectively). FIGURE 7-22 NEPHROPATHIES Nephropathies associated with HIV. The literature refers to the glomerulosclerosis associated ASSOCIATED W ITH with human immunodeficiency virus (HIV) as HIV-associated nephropathy. However, HIV- HUM AN IM M UNODEFICIENCY associated nephropathies may include a spectrum of renal diseases, including HIV-associated VIRUS INFECTION glomerulosclerosis, HIV-associated immune-complex glomerulonephritis (focal or diffuse proliferative glomerulonephritis, immunoglobulin A nephropathy) and HIV-associated hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP). Diffuse Focal segmental or global glomerulosclerosis mesangial hyperplasia and minimal change disease also may be associated with HIV, particu- larly in children. Therefore, the nomenclature of HIV-associated nephropathies should be Diffuse and global mesangial hyperplasia amended to list the associated qualifying histologic feature [156]. All types of glomeru- Minimal change disease lopathies have been observed in patients with HIV-infection. Their prevalence and severity Others: vary with the population studied. Focal segmental or global glomerulosclerosis is most preva- Immune-complex glomerulopathies lent in black adults. In whites, proliferative and other types of glomerulonephritis predomi- Hemolytic uremic syndrome, thrombotic nate. In children with perinatal acquired immunodeficiency syndrome, glomerulosclerosis, thrombocytopenic purpura diffuse mesangial hyperplasia, and proliferative glomerulonephritis are equally prevalent. Thus, concern existed Glomerulosclerosis that this entity m erely represented the older heroin nephropathy Diff. H owever, in a M iam i- 75 based population of adult non-IV drug users with glomerular disease and H IV infection, 55% of Caribbean and Am erican blacks had severe glom erulosclerosis, 9% had m ild focal glom erulosclerosis, 50 and 27% had diffuse m esangial hyperplasia. In contrast, two of 12 (17% ) whites had a m ild form of focal glom erulosclerosis, 75% had diffuse m esangial hyperplasia, and none had severe glom eru- 25 losclerosis. These m orphologic differences were reflected in m ore severe clinical presentations, with blacks m ore likely to m anifest proteinuria in the nephrotic range (>3. W hites often had Caribbean blacks American blacks W hites (n=22) (n=11) (n=12) proteinuria under 2 g/24 h and serum creatinine values less than 2 m g/dL [162]. In blacks, glom erulosclerosis has been described in all groups at risk for HIV infection, including IV drug users, homo- FIGURE 7-23 sexuals, patients exposed to heterosexual transmission or to contami- Glom erulosclerosis associated with H IV. In the United States, H IV- nated blood products, and children infected perinatally [163,164]. This entity initially was consid- striking predom inance in blacks independent of IV drug abuse ered with skepticism because it was not seen in San Francisco, [165]. Racial factors explain the absence of H IV-associated where m ost patients testing seropositive were white hom osexuals glom erulosclerosis in whites and Asians. In N ew York, patients with glom erulosclerosis were racial predilection is unknown. The onset of the October 1985: A dockworker until 3 months before admission, when nephropathy is often abrupt, with uremia and Viral syndrome. He massive nonselective proteinuria (sometimes nine, 0. These fulminant December 1986: periorbital and trace ankle edema, interstitial pneu- monia, and diffuse adenopathies. Serum creatinine lesions may present as acute renal failure in Fever, fatigue, cough. In other used intravenous drugs; 11-cm, echogenic kidneys neys. Renal biopsy showed focal segmental glomeru- patients, minimal proteinuria and azotemia at February 1987: losclerosis. Lymph node biopsy showed presentation increase insidiously over a period 3+ edema. This patient returned to of several months until a nephrotic syndrome tinine, 11. Hypertension and glomerulosclerosis peripheral edema may be absent even in the May 1987: context of advanced renal insufficiency or 100 lbs; patient died after 3 months of hemodialysis severe nephrotic syndrome. PATHOLOGIC FEATURES OF GLOM ERULOSCLEROSIS ASSOCIATED W ITH HUM AN IM M UNODEFICIENCY VIRUS INFECTION Collapsed glomerular capillaries Visceral glomerular epitheliosis Microcystic tubules with variegated casts Focal tubular simplification Interstitial lymphocytic infiltration Endothelial reticular inclusions FIGURE 7-26 Pathologic features of glom erulosclerosis. N one of the features list- FIGURE 7-25 ed is pathognom onic. The concom itant presence of glom erular and Ultrasonography of a hyperechogenic 15-cm kidney in a patient tubular lesions with tubuloreticular inclusions in the glom erular with H IV-associated glom erulosclerosis, nephrotic syndrom e, and and peritubular capillary endothelial cells, however, is highly sug- renal failure.